New therapeutic approaches for metastatic thyroid carcinoma

Lancet Oncology

Volumn 8, Issue 2, 2007, Pages 148-156

  Baudin, Eric ^a   Schlumberger, Martin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

17 N ALLYLAMINO 17 DEMETHOXY GELDANAMYCIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; INTERLEUKIN 2; IODINE 131; MITOXANTRONE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SOMATOSTATIN DERIVATIVE; SORAFENIB; TAXANE DERIVATIVE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

AGE DISTRIBUTION; ANGIOGENESIS; BONE METASTASIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; DRUG UPTAKE; EPIDEMIOLOGICAL DATA; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC THYROIDITIS; METASTASIS; MONOTHERAPY; NONHUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT PLANNING; TUMOR DIFFERENTIATION; UNSPECIFIED SIDE EFFECT;

HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS;

EID: 33846490718     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70034-7     Document Type: Review

References (73)

1. Colonna M., Grosclaude P., Remontet L., et al. Incidence of thyroid cancer in adults recorded by French cancer registries. Eur J Cancer 38 (2002) 1762-1768
2. Davies L., and Welch H. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 (2006) 2164-2167
3. Schlumberger M., Filetti S., and Hay I. Non toxic goiter and thyroid neoplasia. In: Larsen R., Kronenberg H., Melmed S., and Polonsky K. (Eds). Williams Textbook of Endocrinology. 10th edn. (2003), WB Saunders Company, Philadelphia 457-490
4. Cooper D., Doherty G., Haugen B., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
5. Pacini F., Schlumberger M., Dralle H., et al., European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
6. Leboulleux S., Rubino C., Baudin E., et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90 (2005) 5723-5729
7. Tubiana M., Schlumberger M., Rougier P., et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55 (1985) 794-804
8. Rouxel A., Hejblum G., Bernier M., et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89 (2004) 5362-5368
9. Kitamura Y., Shimizu K., Nagahama M., et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84 (1999) 4043-4049
10. Carmen F., Eustatia-Rutten A., Corssmit E., et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 313-319
11. Durante C., Haddy N., Baudin E., et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892-2899
12. Casara D., Rubello D., Saladini G., et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34 (1993) 1626-1631
13. Dinneen S., Valimaki M., Bergstralh E., et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80 (1995) 2041-2045
14. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1 (2005) 32-40
15. Maxon H., and Smith H. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19 (1990) 685-718
16. Kouvaraki M., Lee J., Shapiro S., et al. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136 (2004) 1183-1191
17. Hay I., Thompson G., Grant C., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 8 (2002) 879-885
18. Pacini F., Cetani F., Miccoli P., et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 18 (1994) 600-604
19. Travagli J., Cailleux A., Ricard M., et al. Combination of radio-iodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83 (1998) 2675-2680
20. Machens A., Hinze R., Thomusch O., and Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26 (2002) 22-28
21. Dralle H., Brauckhoff M., Machens A., and Gimm O. Surgical management of advanced thyroid cancer invading the aerodigestive tract. In: Clark O., Duh Q., and Kebebew E. (Eds). Textbook of Endocrine Surgery. 2nd edn. (2005), Elsevier Saunders, Philadelphia 318-333
22. Bernier M., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86 (2001) 1568-1573
23. 18F] Fluoro-2-Deoxy-D-Glucose positron emission tomography. J Clin Endocrinol Metab 91 (2006) 498-505
24. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
25. Shimaoka K., Schoenfeld D., De Wys W., et al. Randomized trial of Doxorubicin versus Doxorubicin plus Cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (1985) 2155-2160
26. Williams S., Birch R., and Einhorn L. Phase II evaluation of Doxorubicin plus Cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70 (1986) 405-407
27. Droz J., Schlumberger M., Rougier P., et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76 (1990) 480-483
28. Santini F., Bottici V., Elisei R., et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87 (2002) 4160-4165
29. Carella C., Mazziotti G., Amato G., et al. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 89 (2004) 3656-3661
30. Robbins R., Hill R., Wang W., et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10 (2000) 177-183
31. Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer 13 (2006) 779-795
32. Fagin J. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183 (2004) 249-256
33. Krause D., and Van Etten R. Tyrosine kinase as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
34. Braga-Brasaria M., and Ringel M. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88 (2003) 1947-1960
35. Ouyang B., Knauf J., Smith E., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12 (2006) 1785-1793
36. Bounacer A., McGregor A., Skinner J., et al. Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene 23 (2004) 7939-7945
37. Shinohara M., Chung Y., Saji M., and Ringel M. AKT in thyroid tumorigenesis and progression. Endocrinology (2006). published online Aug 31. DOI:10.1210/en.2006-0937
38. Nikiforova M., Lynch R., Biddinger P., et al. RAS point mutations and PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88 (2003) 2318-2326
39. Fagin J., Matsuo K., Karmakar A., et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91 (1993) 179-184
40. Bunone G., Vigneri P., Mariani L., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with pathological features. Am J Pathol 155 (1999) 1967-1976
41. Lennard C., Patel A., Wilson J., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 (2001) 552-558
42. de la Torre N., Buley I., Wass J., and Turner H. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 13 (2006) 931-944
43. Schoenberger J., Grimm D., Kossmehl P., et al. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145 (2004) 1031-1038
44. Younes M., Yazici Y., Kim S., et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res 12 (2006) 3425-3434
45. Filetti S., Bidart J., Arturi F., et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141 (1999) 443-457
46. Knauf J., Ma X., Smith E., et al. Targetted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo differentiation. Cancer Res 65 (2005) 4238-4245
47. Porra V., Ferraro-Peyret C., Durand C., et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 90 (2005) 3028-3035
48. Xing M. Gene Methylation in Thyroid Tumorigenesis. Endocrinology (2006). published online Aug 31. DOI:10.1210/en.2006-0927
49. Santoro M., and Carlomagno F. Drug insight: small molecules inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2 (2006) 42-52
50. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potentially inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66 (2006) 8715-8721
51. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 (2006) 326-334
52. Kim D., Jo Y., Jung H., et al. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases. J Clin Endocrinol Metab 91 (2006) 4070-4076
53. Vidal M., Wells S., Ryan A., and Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for Type 2 Multiple Endocrine Neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65 (2005) 3538-3541
54. Boughton D, Rosen L, Van Vugt A, et al. Safety and antitumor activity of AMG 706 in patients with thyroid cancer: a subset analysis from a phase I dose-finding study. ASCO meeting, Atlanta, Georgia, USA, June 2006.
55. Kim S, Rosen LS, Cohen EE, et al. A phase II study of axinitib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. ASCO meeting, Atlanta, Georgia, USA, June 2006.
56. Kloos R, Ringel M, Knopp M, et al. Significant clinical and biological activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study. ASCO meeting, Atlanta, Georgia, USA, June 2006.
57. Gruning T., Tiepolt C., Zophel K., et al. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur J Endocrinol 148 (2003) 395-402
58. Haugen B., Larson L., Pugazhenthi U., et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89 (2004) 272-280
59. Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228) increase expression of Na+/I- symporter and iodide accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 3430-3435
60. Puppin C., D'Aurizio F., D'Elia A., et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146 (2005) 3967-3974
61. Luong Q., O'Kelly J., Braunstein G., et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12 (2006) 5570-5577
62. Venkataraman G., Yatin G., Marcinek R., and Ain K. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab 84 (1999) 2449-2457
63. 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology 138 (1977) 4493-4496
64. Mandell R., Mandell L., and Link C. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59 (1999) 661-668
65. Boland A., Ricard M., Opolon P., et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60 (2000) 3484-3492
66. Spitzweg C., and Morris J. Gene therapy for thyroid cancer: current status and future prospects. Thyroid 14 (2004) 424-434
67. Schiff B., McMurphy A., Jasser S., et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10 (2004) 8594-8602
68. Mitsiades C., Kotoula V., Poulaki V., et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91 (2006) 3662-3666
69. Brierley J., Tsang R., Glisson B., et al. Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. American Thyroid Association meeting, Phoenix, October 2006. Thyroid 16 (2006) 857
70. Mrozek E., Kloos R., Ringel M., et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 2201-2204
71. Teunissen J., Kwekkeboom D., and Krenning E. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17 (2006) 19-25
72. O'reilly M. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16 (2006) 45-50
73. Hedinger C., Williams E., and Sobin L. Histological typing of thyroid tumours. International Histological Classification of Tumours. World Health Organization 1988. 2nd edn. vol 11 (1988), Springer-Verlag, Berlin